




# Supplementary Materials



**Supplementary Figure 1: TKIs decrease cell proliferation in CML cells.** K562, KU812 and KCL22 CML cells were treated with either imatinib (A-C) or dasatinib (D-F) for 24 or 48hrs. Following this time, MTT cell proliferation assays were performed and this data is displayed in the figure. Results were analysed via two-way ANOVAs with a Dunnett's post hoc test. Statistical tests compared results between the treated cells and the untreated control, as well as between 24 and 48hrs for each concentration. \* =  $P < 0.05$ , \*\* =  $P < 0.01$ , # =  $P < 0.001$ , ## =  $P < 0.0001$ . N=3. Values displayed as mean $\pm$ SEM.



**Supplementary Figure 2: TKIs decrease cell proliferation in CML cells.** K562, KU812 and KCL22 CML cells were treated with either ponatinib (A-C) or GNF-5 (D-F) for 24 or 48hrs. Following this time, MTT cell proliferation assays were performed and this data is displayed in the figure. Results were analysed via two-way ANOVAs with a Dunnett's post hoc test. Statistical tests compared results between the treated cells and the untreated control, as well as between 24 and 48hrs for each concentration. \* =  $P < 0.05$ , \*\* =  $P < 0.01$ , # =  $P < 0.001$ , ## =  $P < 0.0001$ .  $N = 3$ . Values displayed as mean  $\pm$  SEM.



**Supplementary Figure 3: Cell viability in CML cells following TKI treatment.** K562 (A), KU812 (B) and KCL22 (C) CML cells were treated with either imatinib, dasatinib, ponatinib or GNF-5 for 24, 48 and 72hrs. Cell viability was then measured using trypan blue. Results were analysed via one-way ANOVAs with a Dunnett's post hoc test. Statistical tests compared results between the treated cells and the untreated control. \* =  $P < 0.05$ , \*\* =  $P < 0.01$ , # =  $P < 0.001$ , ## =  $P < 0.0001$ . N=3. Values displayed as mean  $\pm$  SEM.